Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TORNALATE vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Bronchodilator for asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Hepatic via sulfation and glucuronidation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 70% bound to plasma proteins, primarily albumin.
55–65% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.4-2.1 L/kg, indicating extensive tissue distribution, particularly to the lungs.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: systemic bioavailability is about 20% due to pulmonary deposition and subsequent absorption; oral bioavailability is low (<5%) due to first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No specific guidelines; caution in severe hepatic impairment due to lack of data.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not approved for pediatric use.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Use with caution; initiate at lower end of dosing range due to potential for increased sensitivity.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None
No FDA black box warning exists for this drug.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias),Hypokalemia,Immediate hypersensitivity reactions
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to TORNALATE or any component
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No known food interactions. Avoid excessive caffeine as it may potentiate stimulant effects.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; second/third trimester: may cause fetal tachycardia, hypoglycemia, and hyperglycemia due to beta agonist activity. Risk of preterm labor and low birth weight with chronic use. Overall, consider risk-benefit; not a major teratogen.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excretion in human milk is unknown; M/P ratio not established. Beta-2 agonists likely present in low amounts. Consider that maternal asthma control is important; benefit of breastfeeding likely outweighs minimal risk if mother is stable. Monitor infant for irritability, tachycardia, or feeding difficulties.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No dose adjustment required for pregnancy per se. However, pregnancy may alter asthma severity; adjust dose to achieve optimal control. Monitoring for maternal tachycardia or hypokalemia may necessitate dose reduction. No established pregnancy-specific pharmacokinetic changes requiring routine dose adjustment.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
TORNALATE (bitolterol mesylate) is a selective beta-2 adrenergic agonist used as a bronchodilator. It has a faster onset than albuterol (within 3–5 minutes) but a shorter duration (3–5 hours). It is primarily indicated for acute bronchospasm in asthma or COPD. Caution in patients with cardiovascular disease, as it may cause tachycardia or arrhythmias. Not a first-line agent due to availability of longer-acting alternatives. Monitor for paradoxical bronchospasm and excessive dosing.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Use only as directed for acute symptoms; do not exceed prescribed dose.,Rinse mouth after inhalation to prevent oral candidiasis.,Seek immediate medical help if symptoms worsen or you need more inhalations than usual.,Inform your doctor about any heart conditions, high blood pressure, or seizures.,Report side effects like chest pain, rapid heartbeat, or worsening breathing.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TORNALATE vs AEROLATE SR, answered by our medical review team.
TORNALATE is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TORNALATE and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TORNALATE is: 2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TORNALATE and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TORNALATE is classified as Category C. TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no kno. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.